Breaking News Instant updates and real-time market news.

NLNK

NewLink Genetics

$4.20

-3.12 (-42.62%)

, INCY

Incyte

$64.02

-19.05 (-22.93%)

07:30
04/09/18
04/09
07:30
04/09/18
07:30

NewLink Genetics downgraded to Hold at SunTrust on Incyte trial failure

As reported late last week, SunTrust analyst Peter Lawson downgraded NewLink Genetics (NLNK) to Hold from Buy and lowered his price target to $5 from $19. Lawson cites the announcement of negative results from the Phase 3 ECHO-301 of epacadostat + Keytruda in melanoma by Incyte (INCY), saying the data also implies a "significant negative read through for NewLink's IDO agent, indoximod". Lawson adds that the results have led him to remove melanoma from his NewLink model and also reduce the probability of success in pancreatic cancer, lowering the probability of adjusted peak sales from $415M to just $11M.

NLNK

NewLink Genetics

$4.20

-3.12 (-42.62%)

INCY

Incyte

$64.02

-19.05 (-22.93%)

  • 23

    Apr

  • 08

    May

  • 12

    Jun

NLNK NewLink Genetics
$4.20

-3.12 (-42.62%)

04/09/18
CANT
04/09/18
DOWNGRADE
Target $7
CANT
Neutral
Cantor downgrades NewLink with $7 target on added indoximod uncertainty
Cantor Fitzgerald analyst Mara Goldstein downgraded NewLink Genetics (NLNK) to Neutral from Overweight and cut her price target for the shares to $7 from $26. The analyst cites NewLink's decision to revisit the indoximod clinical program as the reason for the downgrade. Goldstein previously highlighted the differentiating factors between indoximod and Incyte's (INCY) epacadostat, but she now has reduced confidence given a "lack of decisive commentary" from NewLink management.
04/09/18
CANT
04/09/18
DOWNGRADE
CANT
Neutral
NewLink Genetics downgraded to Neutral from Overweight at Cantor Fitzgerald
04/09/18
JEFF
04/09/18
DOWNGRADE
Target $4
JEFF
Hold
NewLink Genetics downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin late Friday downgraded NewLink Genetics (NLNK) to Hold from Buy and cut his price target for the shares to $4 from $17. The stock closed Friday down 43%, or $3.12, to $4.20. The analyst does not see a scenario in which the company's IDO inhibitor can avoid the same fate as Incyte and Merck's epacadostat plus Keytruda failed study.
04/09/18
BARD
04/09/18
DOWNGRADE
BARD
Neutral
NewLink Genetics downgraded to Neutral from Outperform at Baird
INCY Incyte
$64.02

-19.05 (-22.93%)

04/09/18
NOMU
04/09/18
NO CHANGE
Target $102
NOMU
Buy
Incyte price target lowered to $102 from $139 at Nomura Instinet
Nomura Instinet analyst Christopher Marai on Friday lowered his price target for Incyte to $102 after the Phase ECHO-301 trial of epacadostat and pembrolizumab in advanced metastatic melanoma was stopped. The analyst keeps a Buy rating on the shares. He tells investors to focus on the company's TKI pipeline.
04/09/18
OPCO
04/09/18
NO CHANGE
Target $65
OPCO
Perform
Incyte price target lowered to $65 from $110 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte (INCY) to $65 from $110 following the update on the termination of ECHO-301 after epacadostat failed to show a PFS or OS benefit when combined with Merck's (MRK) Keytruda versus Keytruda alone. While the company plans to conduct subgroup analyses of ECHO-301 looking at various biomarkers such as PD-L1 expression and tumor mutational burden which may provide additional insights, the analyst sees no reason at this time to continue development of epacadostat as he considers it highly unlikely to demonstrate efficacy in other tumor types and/or combinations. Olson reiterates a Perform rating on Incyte's shares.

TODAY'S FREE FLY STORIES

GPS

Gap

$28.28

-1.275 (-4.31%)

14:35
04/20/18
04/20
14:35
04/20/18
14:35
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$84.12

-1.53 (-1.79%)

14:33
04/20/18
04/20
14:33
04/20/18
14:33
Conference/Events
Philip Morris management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ALXN

Alexion

$105.99

-5.75 (-5.15%)

14:30
04/20/18
04/20
14:30
04/20/18
14:30
Recommendations
Alexion analyst commentary  »

Brazilian generic risk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

14:30
04/20/18
04/20
14:30
04/20/18
14:30
General news
Action Economics Survey results »

Action Economics Survey…

UCBI

United Community Banks

$32.40

0.27 (0.84%)

14:29
04/20/18
04/20
14:29
04/20/18
14:29
Syndicate
Breaking Syndicate news story on United Community Banks »

United Community Banks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

HRTX

Heron Therapeutics

$30.40

0.6 (2.01%)

14:24
04/20/18
04/20
14:24
04/20/18
14:24
Recommendations
Heron Therapeutics analyst commentary  »

Helsinn CINV product no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TGI

Triumph Group

$26.05

-0.2 (-0.76%)

14:20
04/20/18
04/20
14:20
04/20/18
14:20
Options
Put buying in Triumph Group »

Put buying in Triumph…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
04/20/18
04/20
14:17
04/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
04/20/18
04/20
14:16
04/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$31.93

0.39 (1.24%)

14:14
04/20/18
04/20
14:14
04/20/18
14:14
Periodicals
Twitter bans ads from Kaspersky Lab, Reuters reports »

Twitter said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.73

0.74 (5.29%)

, WAB

Wabtec

$88.35

4.61 (5.51%)

14:07
04/20/18
04/20
14:07
04/20/18
14:07
Periodicals
GE explores merging transport unit with Wabtec, Reuters says »

GE (GE) is looking into…

GE

General Electric

$14.73

0.74 (5.29%)

WAB

Wabtec

$88.35

4.61 (5.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 24

    Apr

  • 25

    Apr

  • 15

    May

  • 12

    Jun

KMB

Kimberly-Clark

$99.75

-3.59 (-3.47%)

14:05
04/20/18
04/20
14:05
04/20/18
14:05
Technical Analysis
Technical Earnings Preview: Kimberly-Clark near 5-year lows ahead of earnings »

The shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 30

    May

DVMT

Dell Technologies

$73.08

-0.81 (-1.10%)

14:05
04/20/18
04/20
14:05
04/20/18
14:05
Options
Dell Technologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

WEN

Wendy's

$17.23

-0.165 (-0.95%)

14:02
04/20/18
04/20
14:02
04/20/18
14:02
Hot Stocks
Wendy's announces 2020 goal of opening over 600 new restaurants globally »

The Wendy's Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 30

    May

14:00
04/20/18
04/20
14:00
04/20/18
14:00
General news
Fed Governor Brainard did not break from the gradualist mantra »

Fed Governor Brainard did…

LITE

Lumentum

$59.70

-0.25 (-0.42%)

13:55
04/20/18
04/20
13:55
04/20/18
13:55
Options
Lumentum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 29

    May

ALXN

Alexion

$104.44

-7.3 (-6.53%)

13:46
04/20/18
04/20
13:46
04/20/18
13:46
Hot Stocks
Alexion drops after Brazil AG says Soliris patent made public »

Shares of Alexion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AKRX

Akorn

$19.61

0.24 (1.24%)

13:45
04/20/18
04/20
13:45
04/20/18
13:45
Options
Akorn call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
04/20/18
04/20
13:45
04/20/18
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY topped…

TGT

Target

$70.52

-0.45 (-0.63%)

13:35
04/20/18
04/20
13:35
04/20/18
13:35
Options
Target put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

IWM

iShares Trust Russell 2000 Index Fund

$155.75

-0.65 (-0.42%)

, RUT

Russell 2000 Index

13:35
04/20/18
04/20
13:35
04/20/18
13:35
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

At time of writing, the…

IWM

iShares Trust Russell 2000 Index Fund

$155.75

-0.65 (-0.42%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$50.43

-0.915 (-1.78%)

, XLRE

Real Estate SPDR

$30.25

-0.25 (-0.82%)

13:33
04/20/18
04/20
13:33
04/20/18
13:33
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

For the last five days,…

XLP

Consumer Staples Sector SPDR

$50.43

-0.915 (-1.78%)

XLRE

Real Estate SPDR

$30.25

-0.25 (-0.82%)

XLK

Technology Select Sector SPDR

$66.26

-0.89 (-1.33%)

XLE

Energy Select Sector SPDR

$73.29

-0.37 (-0.50%)

XLB

S&P Select Materials SPDR

$58.95

-0.41 (-0.69%)

XLF

Financial Select Sector

$27.94

0.065 (0.23%)

SPY

SPDR S&P 500 ETF Trust

$266.75

-2.09 (-0.78%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$50.25

0.5 (1.01%)

13:25
04/20/18
04/20
13:25
04/20/18
13:25
Options
Scientific Games call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ALXN

Alexion

$110.26

-1.48 (-1.32%)

13:21
04/20/18
04/20
13:21
04/20/18
13:21
Periodicals
Brazil can produce generic Soliris after breaking Alexion patent, Bloomberg says »

Brazil's Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

WAB

Wabtec

$82.74

-1 (-1.19%)

, GE

General Electric

$14.46

0.47 (3.36%)

13:18
04/20/18
04/20
13:18
04/20/18
13:18
Hot Stocks
Wabtec rises after report of talks for GE rail business deal »

Shares of Wabtec (WAB)…

WAB

Wabtec

$82.74

-1 (-1.19%)

GE

General Electric

$14.46

0.47 (3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 24

    Apr

  • 25

    Apr

  • 15

    May

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.